Carbamazepine

證據等級: L5

預測適應症: 10 個

Carbamazepine: From Epilepsy & Trigeminal Neuralgia to Trigeminal Nerve Neoplasm

One-Sentence Summary

Carbamazepine (CBZ) is a well-established antiepileptic and analgesic agent, clinically used for partial seizures, generalized tonic-clonic seizures, and trigeminal neuralgia through voltage-gated sodium channel blockade. The TxGNN model predicts it may be effective for Trigeminal Nerve Neoplasm with a score of 99.998%, supported by 1 clinical trial (not yet recruiting; disease entity mismatch) and 20 publications retrieved for evaluation. Critical semantic caution: The majority of retrieved evidence pertains to trigeminal neuralgia, not trigeminal nerve neoplasm — these are distinct disease entities, and the TxGNN prediction likely reflects knowledge-graph label proximity rather than a genuine antitumor signal.

Quick Overview

Item	Content
Original Indication	No US FDA license records retrieved (data gap); CBZ is clinically established for epilepsy and trigeminal neuralgia
Predicted New Indication	Trigeminal Nerve Neoplasm
TxGNN Prediction Score	99.998%
Evidence Level	L4
US Market Status	No records found (data gap — manual FDA Orange Book verification recommended)
Number of NDAs	0 (data gap)
Recommended Decision	Research Question

Why Is This Prediction Reasonable?

Carbamazepine is the gold-standard first-line treatment for trigeminal neuralgia and a widely prescribed antiepileptic. Its primary mechanism is voltage-gated sodium channel blockade in a use-dependent manner — suppressing repetitive, high-frequency neuronal firing at the site of ectopic discharge. Preclinical evidence (PMID 3181365) directly demonstrates that intravenous CBZ inhibits spontaneous ectopic discharges from experimental neuromas in both A-alpha/beta and A-delta fibers at clinically relevant serum concentrations.

Trigeminal nerve neoplasms — including schwannomas, meningiomas, sarcoid granulomas, and malignant lymphomas — can compress or infiltrate the trigeminal nerve, producing secondary neuralgia-like pain that is mechanistically similar to classical trigeminal neuralgia. In this narrow context, CBZ may provide symptomatic pain relief by suppressing ectopic discharges triggered by tumor compression. Several case reports in the evidence base (PMID 30741017, PMID 25142539) describe patients presenting with facial pain initially managed with CBZ who were later found to harbor trigeminal nerve lymphoma — confirming that CBZ addresses the pain symptom rather than the underlying tumor.

However, CBZ has no known antitumor mechanism. The TxGNN high prediction score is most plausibly driven by disease-label semantic overlap between “trigeminal nerve neoplasm” and “trigeminal neuralgia” within the knowledge graph’s disease node structure, rather than a genuine repurposing opportunity targeting the neoplasm itself. This prediction should be interpreted as a symptom-management overlap, not a novel oncological indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06853119	N/A	Not Yet Recruiting	120	MRI-based study of brain network dynamics, microstructure, and blood-brain barrier integrity in trigeminal neuralgia patients — evaluates neural plasticity mechanisms. Disease entity mismatch: this trial studies neuralgia, not neoplasm; no treatment intervention data applicable

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36824641	2022	Review	Acta Clinica Croatica	Comprehensive treatment options for trigeminal neuralgia; acknowledges tumor compression as a secondary cause; CBZ confirmed as first-line pharmacotherapy
17997704	2007	Review	Expert Review of Neurotherapeutics	TN among the most painful human conditions; etiology involves vascular compression causing demyelination and aberrant discharge; CBZ is established first-line; surgical options reviewed
30741017	2023	Case Report	British Journal of Neurosurgery	Primary neurolymphomatosis of the trigeminal nerve presenting as facial pain; CBZ prescribed without symptom improvement; MRI revealed nerve swelling and mass in Meckel’s cave — directly demonstrates CBZ’s failure against the underlying neoplasm
25142539	2014	Case Report	Rinsho Shinkeigaku	Malignant lymphoma with perineural spread along trigeminal nerve initially presenting as classical TN; improved briefly with CBZ, then became refractory as additional cranial nerve symptoms emerged — confirms CBZ manages pain symptom only
3181365	1988	Animal Study	Experimental Neurology	IV CBZ produced immediate inhibition of spontaneous ectopic discharges from saphenous neuromas at doses of 2.51–11.2 mg/kg; serum levels matched therapeutic range — core mechanistic rationale for symptom suppression
9109911	1997	Case Report	Neurology	Post-irradiation neuromyotonia in bilateral facial and trigeminal nerve distribution responded to CBZ — radiation-induced nerve injury model, not neoplasm
12590697	2003	Case Report	Neurosurgery	Isolated trigeminal nerve sarcoid granuloma mimicking trigeminal schwannoma on imaging; differential diagnosis and radiological features compared
32454201	2020	Case Report	World Neurosurgery	Trigeminal schwannoma of pterygopalatine fossa (0.1–0.4% of intracranial tumors); resected via endoscopic endonasal approach — surgical management, no CBZ data
33989821	2021	Case Report	World Neurosurgery	Petroclival meningioma causing TN in <5% of cases; encased fifth nerve resected via Kawase approach — surgical management, no CBZ data
26768887	2016	Case Report	Turkish Neurosurgery	Pituitary adenoma with cavernous sinus invasion presenting as isolated trigeminal neuralgia; extremely rare entity requiring surgical decompression

US Market Information

No US FDA license records were retrieved for Carbamazepine in this Evidence Pack. This represents a data gap in the automated query pipeline. Carbamazepine (marketed as Tegretol®, Carbatrol®, Epitol®, Equetro®, and Carnexiv® IV formulation) is in fact an established marketed drug in the United States with approved indications for epilepsy and trigeminal neuralgia. Manual verification via the FDA Orange Book is strongly recommended before regulatory assessment.

Safety Considerations

No TFDA or US FDA warning/contraindication data was retrieved in this Evidence Pack. Please refer to the package insert for complete safety information.

Clinically established safety signals for Carbamazepine (requiring formal verification from package insert):

Aplastic anemia and agranulocytosis: Black Box warning; rare but potentially fatal; baseline CBC with differential required before initiation
Serious dermatologic reactions: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN); significantly elevated risk in patients carrying the HLA-B*1502 allele (prevalence in East and Southeast Asian populations)
Teratogenicity: Associated with spina bifida and neural tube defects; Category D in pregnancy
Hyponatremia/SIADH: Clinically significant, especially in elderly patients
Drug interactions: Potent CYP3A4 inducer with extensive DDI profile; no formal DDI data retrieved in this pack

Conclusion and Next Steps

Decision: Research Question (Hold)

Rationale: The TxGNN prediction score of 99.998% for trigeminal nerve neoplasm most likely reflects disease-label semantic proximity within the knowledge graph — the “trigeminal” node connects neuralgia and neoplasm — rather than a genuine antitumor repurposing opportunity. CBZ’s symptom-management role in neoplasm-induced neuropathic pain is already within the drug’s established standard-of-care use (treating secondary trigeminal neuralgia), and does not constitute a novel repurposing indication. Evidence level L4 (one animal study as the core mechanistic paper; case reports confirming CBZ addresses symptoms, not the tumor) is insufficient to advance to clinical development for the neoplasm itself.

To proceed, the following is needed:

Clarify the research question: Is the target “CBZ for pain management secondary to trigeminal nerve neoplasm” (symptom relief — already within standard of care) or “CBZ as an antineoplastic agent” (no established biological basis)?
Retrieve US FDA regulatory data: Confirm CBZ’s approved US indications, Black Box warnings, and complete contraindication list from the FDA Orange Book and full prescribing information
Confirm MOA data from DrugBank: Formally document sodium channel blocking mechanism and any secondary pharmacological targets
Knowledge graph audit: Investigate whether the TxGNN training data conflates “trigeminal neuralgia” and “trigeminal nerve neoplasm” disease nodes — if confirmed, the high score reflects a label artifact rather than a biological prediction
Disease-specific literature search: If the intent is symptomatic management in neoplasm patients specifically, a focused PubMed search on “carbamazepine + trigeminal nerve tumor/neoplasm/schwannoma + pain management” with a systematic review methodology would be more informative than the current broad query
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.